Literature DB >> 16961270

Effects of insulin treatment on intracellular lipid metabolism in liver of diabetic rats.

Lulu Chen1, Yongbo Wang, Min Zhou, Baoping Wang.   

Abstract

The effects and the mechanism of insulin treatment on intracellular lipid metabolism in liver of diabetic rats were evaluated. Type 2 diabetic rats were induced by injecting the streptozotocin (25 mg/kg) and fat rich food. According to the results of oral glucose tolerance test (OGTT) and glucose-induced insulin secretion test (IRT), the rats were divided into two groups: untreated group (UT) and insulin-treated group (IT). Normal rats (NC) served as controls. The treatment with either Humulin N (4--6 U/kg every day), or saline lasted for 4 weeks. Body weight, OGTT, IRT, blood lipids, intracellular lipids in liver, hepatic fatty acid oxidation and the activity of fatty acid synthase (FAS) were detected. The change of liver histology was observed. The insulin sensitivity index (ISI) was applied to assess the status of insulin resistance. The results showed that as compared with NC group, the plasma and hepatic intracellular Triglyceride (TG), total cholesterol (TC) and free fatty acids (FFAs) were increased significantly in UT group (P < 0.05), and lipid droplets could be seen dispersedly in the liver specimens, the hepatic fatty acid oxidation was increased markedly (P < 0.05), while the fatty acid synthase activity decreased (P < 0.05). Insulin treatment resulted in a further accumulation of lipids in liver by 55.7%, 19.87% and 22.2% increase in TG, TC, FFAs respectively. The size of hepatocytes was enlarged and the cells were filled with fat drops. Plasma lipids showed little decrease and still significantly higher than those in NC group after the insulin treatment. Meanwhile, insulin treatment was companied by 20% decrease in the rate of fatty acid oxidation and 31% increase in hepatic FAS activity compared to UT group. It was concluded that treatment with insulin on type 2 diabetic rat increases hepatic intracellular lipid accumulation by inhibiting hepatic fatty acid oxidation and activating FAS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961270     DOI: 10.1007/bf02829552

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Effects of dietary coconut oil on fatty acid oxidation capacity of the liver, the heart and skeletal muscles in the preruminant calf.

Authors:  C Piot; J F Hocquette; J H Veerkamp; D Durand; D Bauchart
Journal:  Br J Nutr       Date:  1999-10       Impact factor: 3.718

3.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; E Bugianesi; M Lenzi; A J McCullough; S Natale; G Forlani; N Melchionda
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

4.  Fatty acid synthase and adipsin mRNA levels in obese and lean JCR:LA-cp rats: effect of diet.

Authors:  G Shillabeer; J Hornford; J M Forden; N C Wong; J C Russell; D C Lau
Journal:  J Lipid Res       Date:  1992-01       Impact factor: 5.922

5.  Metformin reverses fatty liver disease in obese, leptin-deficient mice.

Authors:  H Z Lin; S Q Yang; C Chuckaree; F Kuhajda; G Ronnet; A M Diehl
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

Review 6.  Hepatic steatosis and type 2 diabetes mellitus.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

7.  Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle.

Authors:  Christian Anderwald; Elisabeth Bernroider; Martin Krssak; Harald Stingl; Attila Brehm; Martin G Bischof; Peter Nowotny; Michael Roden; Werner Waldhäusl
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats.

Authors:  Núria Roglans; Elena Sanguino; Cristina Peris; Marta Alegret; Manuel Vázquez; Tomás Adzet; Cristina Díaz; Gonzalo Hernández; Juan C Laguna; Rosa M Sánchez
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

10.  Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met.

Authors:  Kengo Tomita; Toshifumi Azuma; Naoto Kitamura; Jiro Nishida; Gen Tamiya; Akira Oka; Sayaka Inokuchi; Takeshi Nishimura; Makoto Suematsu; Hiromasa Ishii
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.